CagriSema Phase 3 miss — pipeline setback; LLY orforglipron/Foundayo advances; oral Wegovy traction
Key Questions
What were the results of Novo Nordisk's CagriSema Phase 3 trials?
CagriSema missed primary endpoints in REDEFINE1/2 trials versus tirzepatide, achieving 20.4% weight loss in non-DM patients and 60% reaching 20%+ loss. Adherence-adjusted results showed 22.7% weight loss; FDA decision expected December 2025.
How does oral Wegovy compare to Eli Lilly's orforglipron?
In the ORION ITC, oral Wegovy 25mg outperformed orforglipron 36mg with 3.2% better weight loss (16.6% edge), 84% patient preference, and fewer dropouts. This data boosted Novo stock by 2.6%.
When is oral Wegovy expected for FDA approval?
FDA approval for oral Wegovy is anticipated in December 2025. It has already seen over 600,000 scripts, attracting needle-phobic patients.
What is the revenue potential for oral Wegovy?
UBS projects $5B in revenue for oral Wegovy due to strong traction and preference over rivals. Novo holds first-to-market advantage.
How many prescriptions have been issued for oral semaglutide?
More than 600,000 prescriptions have been issued for the oral weight loss drug. Novo CEO notes the market has only scratched the surface.
What is Eli Lilly's response in the GLP-1 space?
Eli Lilly's Foundayo has been approved, giving Novo first-to-market with oral Wegovy. LLY also advances orforglipron and UBT251 in Phase 2.
What other pipeline developments involve Novo Nordisk?
Novo has partnerships like Aspect for Type 1 diabetes and Awiqli FDA approval in March 2026. These counter LLY rivalry.
Why do patients prefer oral weight loss drugs?
Americans prefer pills for cost and convenience, as per surveys. Oral Wegovy's data shows high preference (84%) over injectables and rivals.
Ph3 REDEFINE1/2 miss vs tirzepatide (20.4% WL non-DM/60% 20%+ loss); Oral Wegovy ORION ITC 25mg beats orforglipron (16.6% WL edge, 600k+ scripts); LLY Foundayo approved; UBT251 Ph2; Awiqli FDA 3/26/26; Aspect Type1.